Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l’Hospital de la Santa Creu I Sant Pau.
Nanoligent uses state-of-the-art protein engineering and nanobiotechnology to develop targeted drug therapy
Nanoligent’s Groundbreaking Drug Targets CXCR4 to Halt Tumor Growth and Metastasis
Our mision is to improve the life of patients by designing new medicines that selectively target the cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs.
Our technology allows the design of new protein conjugates organized as nanoparticles and capable of targeting specific biological systems. This protein architecture is highly stable upon administration in vivo, allowing not only targeted systemic circulation but also site-specific drug delivery.
Our aim is to advance our first candidate as an affordable cancer therapy for the many with a high social impact. The technology we’ve developed holds promise beyond cancer, potentially revolutionizing targeted drug delivery towards different biomarkers.
We’re a team of visionaries and experts committed to changing the future of medicine. Founded in 2017 by distinguished professors Dr. A. Villaverde, Dr. E. Vázquez, Dr. R. Mangues, and entrepreneur Dr. M. Rodríguez, Nanoligent boasts a leadership team with unparalleled expertise in nanobiotechnology and oncology.
As we embark on this journey through the world of scientific publications, we invite you to join us in the pursuit of knowledge and the quest for solutions to some of the most pressing questions in our fields. From groundbreaking research to cutting-edge discoveries, these publications represent a collective effort to expand the frontiers of human knowledges.
We believe in what we do and we are fully devoted to it.
Superior scientific innovation - groundbreaking solutions.
Fostering synergy across diverse disciplines, academic entities, medical professionals, and external organizations.
A deep focus in prioritizing patients and delivering personalized therapies.
Financiado por la Unión Europea – NextGenerationEU. Sin embargo, los puntos de vista y las opiniones expresadas son únicamente los del autor o autores y no reflejan necesariamente los de la Unión Europea o la Comisión Europea. Ni la Unión Europea ni la Comisión Europea pueden ser consideradas responsables de las mismas.